Health Care. Life Sciences.
IRA Capital invests in the next generation of pharmaceutical, biotechnology, medical device, diagnostics, and life science companies. The platform focuses on businesses that are advancing innovation, expanding patient access to care, and delivering measurable improvements in clinical outcomes.
IRA targets companies developing differentiated therapeutics, enabling technologies, precision diagnostics, and next-generation medical devices that address unmet medical needs. The firm prioritizes scalable platforms supported by strong intellectual property, regulatory pathways, and experienced management teams capable of navigating complex development and commercialization cycles.
By aligning capital with science-driven innovation and mission-oriented operators, IRA seeks to build a portfolio positioned at the forefront of medical advancement while generating compelling long-term risk-adjusted returns.
Featured Transaction
Featured Transaction: ExThera Medical Corporation
IRA Ventures invested in ExThera Medical Corporation, a medical technology company founded in 2008 at the Karolinska Institute in Stockholm. ExThera develops and manufactures extracorporeal blood filtration devices designed to remove pathogens from the bloodstream in critically ill patients.
The company’s flagship product, the Seraph 100, is the first and only commercially available pathogen-agnostic hemoadsorption therapy. The device is CE marked in Europe and received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration for the treatment of SARS-CoV-2 during the COVID-19 pandemic. The Seraph 100 is designed to reduce bloodstream pathogens without reliance on pathogen-specific identification, offering a differentiated approach in the management of severe infections.
ExThera’s extracorporeal technologies have demonstrated life-saving potential across a broad range of critically ill patient populations. The company is supported by an expanding body of independent clinical and health economic data, participation in the DARPA Dialysis-Like Therapeutics program, and successful clinical utilization across both U.S. and European markets. IRA’s investment aligns with its strategy of backing innovative healthcare platforms that address urgent unmet medical needs while positioning for scalable commercial adoption.